Sun Lili, Feng Jinqiu, Ma Lihua, Liu Wei, Zhou Zengtong
Department of Stomatology, Tianjin Third Central Hospital, Tianjin Key Laboratory of Artificial Cell, Tianjin, China.
Ann Diagn Pathol. 2013 Dec;17(6):486-9. doi: 10.1016/j.anndiagpath.2013.06.004. Epub 2013 Aug 2.
Oral lichen planus (OLP) is a potentially malignant disorder associated with an increased risk for progression to oral squamous cell carcinoma (OSCC). The objective of this study to determine protein expression of cancer stem cell marker CD133 in tissue samples of patients with OLP and evaluate the correlation between CD133 expression and the risk of progression to OSCC. In this longitudinal case-control study, a total of 110 patients with OLP who received a mean follow-up of 56 months were enrolled, including 100 patients who did not progress to OSCC and 10 patients who had progressed to OSCC. CD133 expression was determined using immunohistochemistry in samples from these patients. Analysis of 10 cases of normal oral mucosa and 6 cases of postmalignant OSCC form previously diagnosed OLP was also performed. The results showed that CD133 expression was observed in 29% cases of nonprogressing OLP and in 80% cases of progressing OLP (P = .002). CD133 was not expressed in normal oral mucosa, but it positively expressed in the 100% cases of OSCC. Logistic regression analysis revealed that the risk of malignant progression in the patients with CD133-positive expression was significantly higher than those with CD133 negativity (odds ratio, 9.79; 95% confidence interval, 1.96-48.92; P = .005). Collectively, CD133 expression was significantly associated with malignant progression in a longitudinal series of patients with OLP. Our findings suggested that CD133 may serve as a novel candidate biomarker for risk assessment of malignant potential of OLP.
口腔扁平苔藓（OLP）是一种潜在的恶性疾病，与进展为口腔鳞状细胞癌（OSCC）的风险增加相关。本研究的目的是确定OLP患者组织样本中癌症干细胞标志物CD133的蛋白表达，并评估CD133表达与进展为OSCC风险之间的相关性。在这项纵向病例对照研究中，共纳入了110例接受了平均56个月随访的OLP患者，其中100例未进展为OSCC，10例进展为OSCC。采用免疫组织化学方法检测这些患者样本中的CD133表达。还对10例正常口腔黏膜样本和6例先前诊断为OLP的恶性OSCC样本进行了分析。结果显示，未进展的OLP患者中有29%检测到CD133表达，进展的OLP患者中有80%检测到CD133表达（P = 0.002）。正常口腔黏膜中未检测到CD133表达，但在100%的OSCC病例中呈阳性表达。逻辑回归分析显示，CD133阳性表达患者的恶性进展风险显著高于CD133阴性患者（比值比，9.79；95%置信区间，1.96 - 48.92；P = 0.005）。总体而言，在一系列纵向的OLP患者中，CD133表达与恶性进展显著相关。我们的研究结果表明，CD133可能作为评估OLP恶性潜能风险的一种新型候选生物标志物。
